Table 3.
Summary of the top findings from Ingenuity Pathway Analysis of the mRNA targets of miR-15b.
Name | p-value | q-value | Ratio |
---|---|---|---|
Canonical pathways | |||
Glioblastoma multiforme signalling | 9.03 × 10−8 | 2.76 × 10−5 | 36/146 (0.247) |
PTEN signalling | 1.51 × 10−7 | 2.76 × 10−5 | 31/118 (0.263) |
STAT3 signalling | 1.75 × 10−7 | 2.76 × 10−5 | 23/73 (0.315) |
TGF-β signalling | 3.78 × 10−7 | 3.90 × 10−5 | 25/87 (0.287) |
PI3K/Akt signalling | 4.13 × 10−7 | 3.90 × 10−5 | 31/123 (0.252) |
Name | p-value range | q-value range | No. molecules |
---|---|---|---|
Molecular and cellular functions | |||
Cell cycle | 5.36 × 10−17–4.34 × 10−4 | 1.13 × 10−13–1.50 × 10−2 | 278 |
Cellular assembly and organization | 1.16 × 10−15–4.29 × 10−4 | 2.20 × 10−12–1.50 × 10−2 | 385 |
Cellular function and maintenance | 1.16 × 10−15–4.34 × 10−4 | 2.20 × 10−12–1.50 × 10−2 | 477 |
Cell death and survival | 1.29 × 10−15–3.91 × 10−4 | 2.20 × 10−12–1.41 × 10−2 | 613 |
Cellular growth and proliferation | 1.02 × 10−14–4.27 × 10−4 | 1.17 × 10−11–1.49 × 10−2 | 621 |
Physiological system development and function | |||
Organismal survival | 9.87 × 10−15–1.73 × 10−8 | 1.17 × 10−11–3.29 × 10−6 | 425 |
Tissue development | 2.15 × 10−13–4.27 × 10−4 | 1.75 × 10−10–1.49 × 10−2 | 596 |
Embryonic development | 6.22 × 10−12–4.12 × 10−4 | 3.04 × 10−9–1.46 × 10−2 | 487 |
Organismal development | 6.22 × 10−12–4.29 × 10−4 | 3.04 × 10−9–1.40 × 10−2 | 598 |
Nervous system development and function | 5.50 × 10−11–4.34 × 10−4 | 1.92 × 10−8–1.50 × 10−2 | 349 |
Diseases and disorders | |||
Cancer | 1.26 × 10−26–4.00 × 10−4 | 2.43 × 10−22–1.42 × 10−2 | 1522 |
Organismal injury and abnormalities | 2.95 × 10−16–4.41 × 10−4 | 6.32 × 10−13–1.51 × 10−2 | 886 |
Reproductive system disease | 2.95 × 10−16–3.91 × 10−4 | 6.32 × 10−13–1.41 × 10−2 | 735 |
Gastrointestinal disease | 4.28 × 10−12–1.00 × 10−4 | 2.22 × 10−9–5.29 × 10−3 | 708 |
Developmental disorder | 2.41 × 10−8–3.91 × 10−4 | 4.38 × 10−6–1.41 × 10−2 | 297 |